We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Autoinjector Pen Helps Multiple Sclerosis Patients

By HospiMedica International staff writers
Posted on 12 Mar 2012
A pen-type intramuscular injector allows multiple sclerosis (MS) patients to self-administer interferon-beta-1a (Avonex). More...


The Avonex Pen is an autoinjector system and titration regimen for patients receiving once-a-week treatment with Avonex for relapsing forms of MS. The device integrates a prefilled syringe and a small, 25 gauge, 15-mm-long needle, and it is intended to reduce anxiety about self-injection. An optional titration regimen at the start of therapy calls for gradual dosage escalation over a four-week period, starting at 7.5 µg and increasing in 7-µg increments each week until the regular dose of 30 µg is reached. A clinical trial in healthy volunteers indicated that the severity of flu-like adverse symptoms was reduced by 76% by titration, compared with starting treatment at the full dosage of 30 µg per week.

During titration, patients must use the conventional prefilled syringes fitted with a special kit for delivering the reduced doses. Once the full dose is reached, patients may then switch to the new autoinjector pen. According to the prescribing information, Avonex should be used with caution in patients with depression or mood disorders or seizures. Patients should also be monitored for signs of hepatic injury, and those with cardiac disease should be closely monitored. Routine periodic blood chemistry and hematology tests are recommended during treatment. The Avonex Pen is a product of Biogen Idec (Weston, MA, USA), and has been approved by the US Food and Drug Administration (FDA).

“Interferon has been an effective treatment for multiple sclerosis for more than 15 years,” said Douglas Williams, PhD, executive vice president of research and development at Biogen Idec. “Data have shown it to have the highest adherence rate among currently marketed injectable therapies; however, anxiety around administration and the potential for flu-like symptoms can be a barrier for some patients.”

Multiple sclerosis is an inflammatory disease in which the fatty myelin sheaths around the axons of the brain and spinal cord are damaged, leading to demyelination and scarring as well as a broad spectrum of signs and symptoms. Disease onset usually occurs in young adults, and it is more common in women. The name multiple sclerosis refers to scleroses (scars), particularly in the white matter of the brain and spinal cord, which is mainly composed of myelin.

Related Links:
Biogen Idec


New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Medical Examination & Procedure Light
Vega 80
New
Immobilization System
Cranial 4Pi Immobilization
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.